Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | EIF4E | P06730 | 1/20 | 0.49 |
| ▸ | EIF4G1 | Q04637 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8595362 | 1.00 | MEN1 (0.53) | MEN1KMT2AMAPTMCL1ALPL | |
| SCHEMBL8595326 | 0.88 | MEN1 (0.52) | MEN1KMT2AMAPTMCL1ALPL | |
| SCHEMBL8595330 | 0.88 | MEN1 (0.52) | MEN1KMT2AMAPTMCL1ALPL | |
| SCHEMBL8592671 | 0.85 | MEN1 (0.50) | MEN1KMT2AMAPTMCL1ALPL | |
| SCHEMBL8592669 | 0.85 | MEN1 (0.50) | MEN1KMT2AMAPTMCL1ALPL | |
| SCHEMBL4887873 | 0.84 | MEN1 (0.55) | MEN1KMT2AMAPTMCL1ALPL | |
| SCHEMBL4887869 | 0.84 | MEN1 (0.55) | MEN1KMT2AMAPTMCL1ALPL | |
| SCHEMBL3899134 | 0.84 | MEN1 (0.65) | MEN1KMT2AMAPTMCL1ALPL | |
| SCHEMBL14025838 | 0.84 | MEN1 (0.65) | MEN1KMT2AMAPTMCL1ALPL | |
| SCHEMBL3899131 | 0.84 | MEN1 (0.65) | MEN1KMT2AMAPTMCL1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830848-B1 | USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS | CELL THERAPEUTICS EUROPE SRL (IT) | 2009-12-16 | — | — | EP | claimed |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | claimed |
| EP-1830848-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | Cell Therapeutics Europe S.R.L. (IT) | 2007-09-12 | — | — | EP | claimed |
| WO-2006066846-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | claimed |
| WO-1998053790-A2 | COMPOUNDS THAT INHIBIT THE BINDING OF VASCULAR ENDOTHELIAL GROWTH FACTOR TO ITS RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-12-03 | — | — | WO | claimed |
| EP-1830848-B1 | USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS | CELL THERAPEUTICS EUROPE SRL (IT) | 2009-12-16 | — | — | EP | disclosed |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1830848-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | Cell Therapeutics Europe S.R.L. (IT) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066846-A1 | USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | EP300, HIF1A, HIF1AN | MEN1 2216/4885KMT2A 1040/4885MAPT 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.